Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

executive vice president of engineering at Masimo. The device gives medical-grade accuracy a cut above most fitness trackers, monitoring the perfusion index of a person, or how well blood is ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Masimo (NASDAQ:MASI ... and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products.

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Masimo MASI2.20%increase; green up pointing triangle said Joe Kiani, who previously informed the board of his decision to resign as chief executive, has been terminated by the company. Kiani’s ...

The company has discontinued several projects, including noninvasive monitoring of cancer, bilirubin, and diabetes, due to lack of expected progress. Masimo Corp (NASDAQ:MASI) is experiencing ...